Gossamer CEO Sheila Gujrathi leaves

  • Push-out Score determined
  • After less than two and a half years in the position
  • Thanks and good wishes for Gujrathi
  • Faheem Hasnain taking over
  • Gujrathi kept it short and said 44 words

(exechange) — San Diego, California, November 16, 2020 — Sheila Gujrathi, chief executive of Gossamer, leaves. As announced by Gossamer Bio Inc. in a news release on Monday, November 16, 2020, Sheila Gujrathi leaves her post as chief executive officer of the clinical-stage biopharmaceutical company after less than two and a half years in the role, effective immediately.

Sheila Gujrathi’s duties as CEO will be taken over by Faheem Hasnain, Co-Founder, former Chief Executive Officer and Chairman of Gossamer Bio Inc.

No reason given

In the announcement, Gossamer did not explicitly explain the reason for Sheila Gujrathi’s move, leaving room for speculation.

Precise information regarding Sheila Gujrathi’s future plans was not immediately available.


Gossamer said: “Mr. Hasnain succeeds Sheila Gujrathi, M.D., a Co-Founder of Gossamer Bio, who served as Chief Executive Officer and President since July 2018.”

Share price decline since November 2019

The announcement follows a decline in Gossamer Bio Inc.’s share price of 58% since November 2019.

In the position of CEO since 2018

Sheila Gujrathi became CEO of the Company in 2018.

Gujrathi will continue in an advisory role to the Company.

Sheila Gujrathi, M.D. is the Company’s Co-Founder and has served as the Company’s President and Chief Executive Officer since July 2018 and as a member of the Company’s board of directors since the Company’s inception in October 2015.

She previously served as the Company’s President and Chief Operating Officer from the Company’s inception until July 2018.

Prior to joining the Company, Gujrathi served as Chief Medical Officer of Receptos from June 2011 until the company’s acquisition by Celgene in August 2015.

Prior to joining Receptos, she was Vice President of the Global Clinical Research Group in Immunology at Bristol-Myers Squibb from 2008 to 2011.

Gujrathi also worked at Genentech from 2002 to 2008 where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group, and served as the Avastin Franchise Team Leader.

From 1999 to 2002, Gujrathi was a management consultant at McKinsey & Company in the healthcare practice where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry.

Gujrathi serves as Chairman of the board of directors of Turning Point Therapeutics, Inc. and previously served as a member of the board of directors of Five Prime Therapeutics, Inc. and Ambrx Inc.

Gujrathi received her B.S. with highest distinction in Biomedical Engineering and her M.D. from Northwestern University in their accelerated Honors Program in Medical Education.

She completed her Internal Medicine Internship and Residency at Brigham and Women’s Hospital, Harvard Medical School.

She received additional training at University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program.

Push-out Score determined

The Push-out Score™ determined by exechange gauges the pressure surrounding the management change on a scale of 0 to 10.

exechange reached out to Gossamer and offered the company the opportunity to comment on the score.

Read the full story in the exechange report 47.2020 ($).